SR 123781
Alternative Names: HDS; SANORG 123781A; SR123781ALatest Information Update: 24 Oct 2021
At a glance
- Originator Organon; sanofi-aventis
- Developer sanofi-aventis
- Class Antithrombotics; Oligosaccharides
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Thrombosis
Most Recent Events
- 01 Mar 2005 This compound is still in active development
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 16 Feb 2004 Phase-II clinical trials in Thrombosis in France (unspecified route)